Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 4, 2012 (14 years ago)

Isoniazid Tablets 300 mg tablets USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications; 36 month stability timepoint

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Isoniazid Tablets 300 mg tablets USP, Rx Only, a) 30 tablets - NDC 61748-013-30, b) 100 tablets - NDC 61748-013-01, Mfd for: VersaPharm Incorporated Marietta, GA 30065-1505, Mfd by: West - Ward Pharmaceutical Corp.., Eatontown, NJ 07724

Affected NDCs 61748-0013-01 61748-0013-30

Compare with the code on your package — it is the most precise check available.

Drug: Isoniazid

Recalling firm
West-ward Pharmaceutical Corp.
NDC code
61748-013-30
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-174-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Isoniazid recalls

See all
Class II · Moderate risk

Isoniazid Tablets

Failed Dissolution Specifications: Stability lots cannot support dissolution past the 36 month time point.

Terminated Dissolution failure West-Ward Pharmaceutical Corp. NDC 0143-1261-01 D-1414-2014
Class II · Moderate risk

Isoniazid

Labeling: Label Mixup: ISONIAZID, Tablet, 300 mg may have potentially been mislabeled as one of the following drugs: hydrOXYzine PAMOATE, Capsule, 100 mg, NDC 00555032402, Pedigree: W003690, EXP: 6/26/2014; CETIRIZINE HCL, Tablet, 5 mg, NDC 00378363501, Pedigree: AD32757_13, EXP: 5/13/2014; RANOLAZINE ER, Tablet, 500 mg, NDC 61958100301, Pedigree: AD32757_47, EXP: 5/13/2014; DULoxetine HCl DR,

Terminated Labeling / mix-up Aidapak Services, LLC D-949-2014

Other recalls by West-ward Pharmaceutical Corp.

All 2012 recalls
Class II · Moderate risk

PredniSONE Tablets USP

Failed Tablet/Capsule Specifications: Discovery of an underweight tablet.

Terminated Failed specification West-Ward Pharmaceutical NDC 0054-4741-25 D-0008-2017
Class III · Low risk

Fentanyl Citrate Inj.

Failed Impurities/Degradation Specifications; 12 month stability testing (Expansion of RES #70548).

Terminated Impurity / degradation West-Ward Pharmaceutical Corp. NDC 0641-6028-25 D-1139-2015
Class III · Low risk

Fentanyl Citrate Inj.

Failed Impurities/Degradation Specifications; 12 month stability testing.

Terminated Impurity / degradation West-Ward Pharmaceutical Corporation NDC 0641-6028-25 D-0420-2015